Immune-related adverse events from combination immunotherapy in cancer patients: A comprehensive meta-analysis of randomized controlled trials
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Background: Although available evidence from clinical trials has shown that immune checkpoint inhibitors (ICIs) combination therapy can lead to a series of immune‐related adverse events (irAEs), the overall risk of irAEs on combination therapy has yet not been systematically reported. Therefore, we performed a meta‐analysis to comprehensively explore the overall risks for irAEs on combination immunotherapy. Methods: PubMed, Embase, and Google Scholar were systematically searched for relevant randomized controlled trials (RCTs) comparing combination immunotherapy to monotherapy. The meta‐analysis was conducted by using Review Manager 5.3. Results: A total of 11 RCTs involving 5307 patients were eligible for this meta‐analysis. The risk ratio for all‐grade diarrhea and all‐grade colitis for combination therapy was 1.95 (95% CI 1.54, 2.46; P < 0.00001) and 4.45 (95% CI 3.04, 6.51; P < 0.00001), respectively. The risk ratio for all‐grade hyperthyroidism and all‐grade hypothyroidism for combination therapy was 2.84 (95% CI 1.71, 4.72; P < 0.0001) and 1.71 (95% CI 1.38, 2.13; P < 0.00001), respectively. The risk ratio for all‐grade increased AST and all‐grade increased ALT was 3.87 (95% CI 2.74, 5.47; P < 0.00001) and 4.29 (95% CI 3.05, 6.04; P < 0.00001), respectively. The risk ratio for all‐grade hypophysitis and all‐grade pneumonitis was 4.24 (95% CI 2.26, 7.98; P < 0.00001) and 2.92 (95% CI 1.60, 5.33; P = 0.0005), respectively. Conclusions: Patients receiving combination immunotherapy are at increased risk of selected all‐grade irAEs. Although fatal high‐grade irAEs is rare, AEs caused by combination immunotherapy should be recognized promptly in order to avoid more serious complications. HighlightsThis is the first and most comprehensive meta‐analysis on the risk of various irAEs following ICIs on combination therapy.Combination immunotherapies are associated with a significant increase in risk of selected all‐grade irAEs.Some fatal irAEs such as pneumonitis and hepatotoxicity should be recognized promptly.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063
Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Research works printed but not linked: 29
- Siegel, 2016, Cancer statistics, 2016, CA Cancer J. Clin., 66, 7
- Wu, 2017, The clinical value of combination of immune checkpoint inhibitors in cancer patients: a meta-analysis of efficacy and safety, Int. J. Cancer, 141, 2562, 10.1002/ijc.31012 · DOI
- Momtaz, 2014, Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway, Pharmgenomics Pers. Med., 7, 357
- Postow, 2015, Immune Checkpoint Blockade in Cancer Therapy, J. Clin. Oncol., 33, 1974, 10.1200/JCO.2014.59.4358 · DOI · Paper page
- Preusser, 2015, Prospects of immune checkpoint modulators in the treatment of glioblastoma, Nat. Rev. Neurol., 11, 504, 10.1038/nrneurol.2015.139 · DOI · Paper page
- Saresella, 2012, The PD-1/PD-L1 pathway in human pathology, Curr. Mol. Med., 12, 259, 10.2174/156652412799218903 · DOI
- Xu, 2018, The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer, Int. J. Cancer, 142, 2344, 10.1002/ijc.31252 · DOI
- Ansell, 2015, PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma, N. Engl. J. Med., 372, 311, 10.1056/NEJMoa1411087 · DOI · Paper page
- Brahmer, 2015, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N. Engl. J. Med., 373, 123, 10.1056/NEJMoa1504627 · DOI · Paper page
- Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N. Engl. J. Med., 373, 1627, 10.1056/NEJMoa1507643 · DOI · Paper page
- Sharma, 2017, Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial, Lancet Oncol., 18, 312, 10.1016/S1470-2045(17)30065-7 · DOI · Paper page
- Weber, 2015, Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial, Lancet Oncol., 16, 375, 10.1016/S1470-2045(15)70076-8 · DOI · Paper page
- Younes, 2016, Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial, Lancet Oncol., 17, 1283, 10.1016/S1470-2045(16)30167-X · DOI · Paper page
- Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N. Engl. J. Med., 363, 711, 10.1056/NEJMoa1003466 · DOI · Paper page
- Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat. Rev. Cancer, 12, 252, 10.1038/nrc3239 · DOI · Paper page
- Hao, 2017, Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: a systematic review and meta-analysis of randomized controlled trials, Medicine (Baltimore), 96, 10.1097/MD.0000000000007325 · DOI
- Brahmer, 2012, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer, N. Engl. J. Med., 366, 2455, 10.1056/NEJMoa1200694 · DOI · Paper page
- Wei, 2017, Risk of gastrointestinal toxicities with PD-1 inhibitors in cancer patients: a meta-analysis of randomized clinical trials, Medicine (Baltimore), 96, 10.1097/MD.0000000000008931 · DOI
- Di Giacomo, 2010, The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications, Semin. Oncol., 37, 499, 10.1053/j.seminoncol.2010.09.007 · DOI · Paper page
- Tandon, 2018, The risk of diarrhea and colitis in patients with advanced melanoma undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis, J. Immunother., 41, 101, 10.1097/CJI.0000000000000213 · DOI
- Boutros, 2016, Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination, Nat. Rev. Clin. Oncol., 13, 473, 10.1038/nrclinonc.2016.58 · DOI · Paper page
- Murakami, 2016, Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma, Clin. Kidney J., 9, 411, 10.1093/ckj/sfw024 · DOI · Paper page
- Larkin, 2015, Combined nivolumab and ipilimumab or monotherapy in untreated melanoma, N. Engl. J. Med., 373, 23, 10.1056/NEJMoa1504030 · DOI · Paper page
- Omuro, 2018, Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143, Neuro-Oncology, 20, 674, 10.1093/neuonc/nox208 · DOI · Paper page
- Long, 2018, Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study, Lancet Oncol., 19, 672, 10.1016/S1470-2045(18)30139-6 · DOI · Paper page
- Higgins, 2011, The Cochrane collaboration's tool for assessing risk of bias in randomised trials, BMJ, 343, d5928, 10.1136/bmj.d5928 · DOI · Paper page
- Wu, 2017, The revolution of lung cancer treatment: from vaccines, to immune checkpoint inhibitors, to chimeric antigen receptor T therapy, Biotarget, 1, 7, 10.21037/biotarget.2017.05.02 · doi:10.21037/biotarget.2017.05.02
- Khalil, 2016, The future of cancer treatment: immunomodulation, CARs and combination immunotherapy, Nat. Rev. Clin. Oncol., 13, 273, 10.1038/nrclinonc.2016.25 · DOI · Paper page
- Nishino, 2016, Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis, JAMA Oncol., 2, 1607, 10.1001/jamaoncol.2016.2453 · DOI · Paper page
Cited by
Therapeutic Targeting of the Tumor Microenvironment
Bejarano, L., Jordāo, M. J. C., & Joyce, J. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1808 · Cited by 1,653
Translational Applications of Hydrogels
Correa, S., Grosskopf, A. K., Lopez Hernandez, H., Chan, D., Yu, A. C., Stapleton, L. M., & Appel, E. A. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01177 · Cited by 1,143
Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review
Oura, K., Morishita, A., Tani, J., & Masaki, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115801 · Cited by 426
Near-infrared photoactivated nanomedicines for photothermal synergistic cancer therapy
Sun, H., Zhang, Q., Li, J., Peng, S., Wang, X., & Cai, R. (2021) · Nano Today · doi:10.1016/j.nantod.2020.101073 · Cited by 332
Resistance to Checkpoint Inhibition in Cancer Immunotherapy
Barrueto, L., Caminero, F., Cash, L., Makris, C., Lamichhane, P., & Deshmukh, R. R. (2020) · Translational Oncology · doi:10.1016/j.tranon.2019.12.010 · Cited by 281
Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy
Zhou, M., Yuan, M., Zhang, M., Lei, C., Aras, O., Zhang, X., & An, F. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113825 · Cited by 92
Validity of data extraction in evidence synthesis practice of adverse events: reproducibility study
Xu, C., Yu, T., Furuya-Kanamori, L., Lin, L., Zorzela, L., Zhou, X., Dai, H., Loke, Y., & Vohra, S. (2022) · BMJ · doi:10.1136/bmj-2021-069155 · Cited by 82
Immune Checkpoint Inhibitor-Related Pneumonitis
Gomatou, G., Tzilas, V., Kotteas, E., Syrigos, K., & Bouros, D. (2020) · Respiration · doi:10.1159/000509941 · Cited by 75
Sanborn, R. E., Hamid, O., de Vries, E. G., Ott, P. A., Garcia-Corbacho, J., Boni, V., Bendell, J., Autio, K. A., Cho, D. C., Plummer, R., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002446 · Cited by 28
Metadata
- Authors
- Zhang, B., Wu, Q., Zhou, Y. L., Guo, X., Ge, J., & Fu, J.
- Venue
- International Immunopharmacology
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 63
- Pages
- 292-298
- ISSN
- 1567-5769 (ISSN-L)
- OpenAlex
- W2885781276
- Cited by
- 103
- References
- 18
- FWCI
- 1.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.